title: Anti-CD20 antibody treatment of non-Hodgkin lymphomas.
abstract: The CD20 antigen characteristic for mature B-cell is also expressed on B-cell Non-Hodgkin lymphomas (NHL). It thus presents a possible target for immunotherapy. NHL respond readily to radio- and/or chemotherapy but this standard treatment bears a high risk of relapse. The specific monoclonal anti-CD20-antibody Rituximab, the first to be approved for clinical use, could be shown to improve response rates, response duration, and survival in NHL when combined with standard therapy. This review details the development, clinical application, and future perspectives of anti-CD20-antibody treatment of NHL, thereby proving the efficiency of immunotherapy via targeting of a tumor associated antigen.
authors.affiliation: Department Radiotherapy, University Hospital, 45122 Essen, Germany. Electronic address: marianne.engelhard@uni-due.de.
authors.forename: Marianne
authors.initials: M
authors.lastname: Engelhard
mesh_terms: D018951:Antigens, CD20 / Q000276:immunology*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000276:immunology; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D000069283:Rituximab / Q000627:therapeutic use*
chemical_list: D018951:Antigens, CD20; D000970:Antineoplastic Agents; D000069283:Rituximab
keywords: Anti-CD20 antibody; CD20 antigen; Immunotherapy; Non-Hodgkin lymphoma; Rituximab